Variability in Activity of Hepatic CYP3A4 in Patients Infected with HIV
- 1 August 2000
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 20 (8) , 898-907
- https://doi.org/10.1592/phco.20.11.898.35262
Abstract
Study Objectives. To evaluate hepatic cytochrome P450 (CYP) 3A4 activity in patients infected with the human immunodeficiency virus (HIV) using the erythromycin breath test (ERMBT), and to examine the relationship of the ERMBT to plasma concentrations of indinavir and nelfinavir. Design. Prospective observational study. Setting. University infectious diseases clinic. Subjects. Thirty‐nine HIV‐positive patients and 47 healthy controls. Intervention. After the ERMBT in patients and controls, 25 patients received indinavir or nelfinavir. Measurements and Main Results. Compared with controls, ERMBT variability was significantly greater in HIV‐positive patients, including a subset of 19 patients receiving no concurrent drugs reported to alter CYP3A4 activity. Correlation between the ERMBT and first‐dose plasma indinavir concentrations nearly reached statistical significance (p=0.07). Conclusion. Variability in hepatic activity of CYP3A4 in HIV‐positive patients may be greater than in controls and may explain some between‐subject variability in plasma concentrations of indinavir. However, clearance mechanisms for protease inhibitors are complex, and if it is important to assess systemic exposure, the ERMBT is not a substitute for direct measurement of plasma concentrations.Keywords
This publication has 41 references indexed in Scilit:
- Gender‐Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in HumansThe Journal of Clinical Pharmacology, 2000
- FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on LabelingThe Journal of Clinical Pharmacology, 1999
- Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1999
- Cytochrome P450 3AClinical Pharmacokinetics, 1999
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Erythromycin Breath Test and Clinical TransplantationTherapeutic Drug Monitoring, 1996
- A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)AIDS, 1996
- P450 EnzymesClinical Pharmacokinetics, 1992
- Drug metabolism in extrahepatic diseasesPharmacology & Therapeutics, 1987
- Effect of disease states on theophylline eliminationJournal of Allergy and Clinical Immunology, 1986